Guenther Koehne
This study will evaluate whether processing blood stem cell transplants using an investigational device (the CliniMACS system) results in less complications for patients undergoing transplant for treatment of a blood malignancy (cancer) or blood disorder.
Inclusion Criteria: * Malignant conditions or other life-threatening disorders correctable by transplant for which CD34+ selected, T-cell depleted allogeneic hematopoietic stem cell transplantation is indicated such as: 1. AML in 1st remission-- for patients whose AML does not have "good risk" cytogenetic features (i.e., t(8;21), (q22; q22.1); RUNX1-RUNX1T1, inv16). 2. Secondary AML in 1st remission 3. AML in 1st relapse or 2nd remission 4. CML not responding adequately to TKI therapy, CML in accelerated phase or blast crisis, or CML in CR after accelerated phase or blast crisis 5.…
Busulfan: 0.8 mg/kg every 6 hours × 12 doses with dose modified according to pharmacokinetics
Melphalan: 70 mg/m²/day × 2
Fludarabine: 25 mg/m²/day × 5
Allogeneic human leukocyte antigen (HLA)-compatible related or unrelated transplants of peripheral blood stem cells (PBSC) depleted of T-cells by positive selection of CD34+ progenitor cells using the CliniMACS system
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.